Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic mps1 kinase inhibitor NMS-P715

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 307-315

  Slee, Roger B ^a,e   Grimes, Brenda R ^a,e,f   Bansal, Ruchi ^a   Gore, Jesse ^b   Blackburn, Corinne ^a   Brown, Lyndsey ^a   Gasaway, Rachel ^a   Jeong, Jaesik ^c   Victorino, Jose ^a,j   March, Keith L ^b,d,g,h,i   Colombo, Riccardo ^k   Herbert, Brittney Shea ^a,e   Korc, Murray ^b,e,f  

^a Departments of Medical and Molecular Genetics   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Departments of Biostatistics   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f IUSCC Center for Pancreatic Cancer Research   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Indiana Center for Vascular Biology   (United States)

ⁱ RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j CALIFORNIA STATE UNIVERSITY   (United States)

^k NERVIANO MEDICAL SCIENCES   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; N-(2,6-DIETHYLPHENYL)-1-METHYL-8-((4-((1-METHYLPIPERIDIN-4-YL)CARBAMOYL)-2-(TRIFLUOROMETHOXY)PHENYL)AMINO)-4,5-DIHYDRO-1H-PYRAZOLO(4,3-H)QUINAZOLINE-3-CARBOXAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRANSCRIPTOME; TTK PROTEIN, HUMAN;

ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; QUINAZOLINES; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTOME;

EID: 84894166131     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0324     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs 2012;21:143-52
3. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37
4. Colombo R, Moll J. Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells. Curr Drug Targets 2010;11: 1325-35
5. Preis M, Korc M. Signaling pathways in pancreatic cancer. Crit Rev Eukaryot Gene Expr 2011;21:115-29
6. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011;71:1858-70
7. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38:1043-8
8. Heim S, Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Abberations of Tumor Cells. 3rd ed. New York: Wiley-Blackwell; 2009
9. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011;71: 3447-52
10. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 2012;13:528-38
11. Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidyselective antiproliferation compounds. Cell 2011;144:499-512
12. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010;70:10255-64
13. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006;12:405-10
14. Schmidt M, Medema RH. Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon? Cell Cycle 2006;5:159-63
15. Yang Z, Loncarek J, Khodjakov A, Rieder CL. Extra centrosomes and/ or chromosomes prolong mitosis in human cells. Nat Cell Biol 2008; 10:748-51
16. Dorer RK, Zhong S, Tallarico JA, Wong WH, Mitchison TJ, Murray AW. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol 2005;15:1070-6
17. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 2005;6:866-72
18. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 2009;106:19108-13
19. Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci U S A 2011;108: 5384-9
20. Tardif KD, Rogers A, Cassiano J, Roth BL, Cimbora DM, McKinnon R, et al. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 2011;10:2267-75
21. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004;101: 8699-704
22. Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 2010;6: 359-68
23. Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, et al. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov 2013;3:198-211
24. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, et al. Antitumor activity of an allosteric inhibitor of centromere-Associated protein-E. Proc Natl Acad Sci U S A 2010;107:5839-44
25. Stolz A, Vogel C, Schneider V, Ertych N, Kienitz A, Yu H, et al. Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res 2009;69:3874-83
26. Hsieh TC, Traganos F, Darzynkiewicz Z, Wu JM. The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol 2007;31:1293-300
27. Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, et al. Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. J Natl Cancer Inst 2013;105:1322-31
28. Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS ONE 2012;7:e31507
29. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3
30. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63
31. Carriere C, Gore AJ, Norris AM, Gunn JR, Young AL, Longnecker DS, et al. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology 2011;141:1091-101
32. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83
33. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D,Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8
34. Hong SJ, Traktuev DO, March KL. Therapeutic potential of adiposederived stem cells in vascular growth and tissue repair. Curr Opin Organ Transplant 2010;15:86-91
35. Grimes BR, Steiner CM, Merfeld-Clauss S, Traktuev DO, Smith D, Reese A, et al. Interphase FISH demonstrates that human adipose stromal cells maintain a high level of genomic stability in long-term culture. Stem Cells Dev 2009;18:717-24
36. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 1989;92: 513-8
37. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55
38. Chen QR, Song YK, Wei JS, Bilke S, Asgharzadeh S, Seeger RC, et al. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 2008;92:195-203
39. Luo J, Schumacher M, Scherer A, Sanoudou D, Megherbi D, Davison T, et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J 2010;10:278-91
40. Stucke VM, Sillje HH, Arnaud L, Nigg EA. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. EMBO J 2002;21:1723-32
41. Gysin S, Paquette J, McMahon M. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Mol Cancer Res 2012;10: 1607-19
42. Slee RB, Steiner CM, Herbert BS, Vance GH, Hickey RJ, Schwarz T, et al. Cancer-Associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene 2012;31: 3244-53
43. Manning AL, Dyson NJ. RB: mitotic implications of a tumour suppressor. Nat Rev Cancer 2012;12:220-6
44. Sihn CR, Suh EJ, Lee KH, Kim TY, Kim SH. p55CDC/hCDC20 mutant induces mitotic catastrophe by inhibiting the MAD2-dependent spindle checkpoint activity in tumor cells. Cancer Lett 2003; 201:203-10
45. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
46. Rubin EH, Gilliland DG. Drug development and clinical trials-The path to an approved cancer drug. Nat Rev Clin Oncol 2012;9:215-22
47. Weidle UH, Maisel D, Eick D. Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genomics Proteomics 2011;8:159-71
48. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92
49. Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122:1138-43
50. Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, et al. Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS ONE 2010;5:e13002.